Patients who achieve partial response or stable disease will receive therapy with obinutuzumab and venetoclax for a total of 2 years. Patients who achieve a complete response will receive obinutuzumab every 2 months for a total of two years. Patients with progressive disease will not continue onto the maintenance arm.